SkyView Investment Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

SkyView Investment Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-10,766	Closed	-$82K	–	333
2025 Q3	$82K	Hold	10,766	–	–	0.01%	273
2025 Q2	$97K	Buy	10,766 +266	+3%	+$2.48K	0.01%	270
2025 Q1	$79K	Sell	10,500 -2,500	-19%	-$20.2K	0.01%	267
2024 Q4	$98K	Hold	13,000	–	–	0.02%	240
2024 Q3	$99K	Buy	13,000 +3,000	+30%	+$22.8K	0.02%	238
2024 Q2	$62K	Hold	10,000	–	–	0.01%	280
2024 Q1	$51K	Buy	+10,000	New	+$56.2K	0.01%	266

Other funds holding BCRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

SkyView Investment Advisors's BCRX Position: Q4 2025 in Review

SkyView Investment Advisors sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2025, closing a stake of 10,766 shares — an estimated $82K sold.

SkyView Investment Advisors first reported a position in BCRX in Q1 2024 and held it in 7 quarters. The position peaked at $99K in Q3 2024. 272 funds tracked by Wall St. Rank hold BCRX as of Q4 2025.

SkyView Investment Advisors reported no remaining BioCryst Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
SkyView Investment Advisors sold 10,766 BioCryst Pharmaceuticals shares in Q4 2025, an estimated $82K.
SkyView Investment Advisors first reported a position in BioCryst Pharmaceuticals in Q1 2024 and held it in 7 quarters.
SkyView Investment Advisors's BioCryst Pharmaceuticals position peaked at $99K in Q3 2024.
272 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2025.

Based on SkyView Investment Advisors's 13F filing for Q4 2025, filed 18 Feb 2026.